ArticleRetrovirology2010
An N-terminally truncated envelope protein encoded by a human endogenous retrovirus W locus on chromosome Xq22.3.
Article in Retrovirology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Human endogenous retrovirus W in multiple sclerosis: transcriptional activity is associated with decline in oligodendrocyte proportions in the white matter of the brain.Journal of neurovirology · 2024Article
- Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Endogenous Retroviruses in Nervous System Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- On the origin of a pathogenic HERV-W envelope protein present in multiple sclerosis lesions.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Reply to Ruprecht and Mayer: Unearthing genomic fossils in the pathogenesis of multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Diseases of the nERVous system: retrotransposon activity in neurodegenerative disease.Mobile DNA · 2019Review
- Review
- Contribution of type W human endogenous retroviruses to the human genome: characterization of HERV-W proviral insertions and processed pseudogenes.Retrovirology · 2016Article
- Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer.Cancer research · 2016Article
- Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.EBioMedicine · 2016Article
- Multiple sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion.BBA clinical · 2015Article
- HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.Retrovirology · 2014Article
- Human endogenous retroviruses and the nervous system.Handbook of clinical neurology · 2014Review
- Comprehensive analysis of human endogenous retrovirus group HERV-W locus transcription in multiple sclerosis brain lesions by high-throughput amplicon sequencing.Journal of virology · 2013Article
- Article
- Expression of human endogenous retrovirus-w including syncytin-1 in cutaneous T-cell lymphoma.PloS one · 2013Article
- Genomic analysis of ERVWE2 locus in patients with multiple sclerosis: absence of genetic association but potential role of human endogenous retrovirus type W elements in molecular mimicry with myelin antigen.Frontiers in microbiology · 2013Article
- Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.Multiple sclerosis (Houndmills, Basingstoke, England) · 2012Article
- Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets.Oncotarget · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe previously showed that the envelope (env) sequence of a human endogenous retrovirus (HERV)-W locus on chromosome Xq22.3 is transcribed in human peripheral blood mononuclear cells. The env open reading frame (ORF) of this locus is interrupted by a premature stop at codon 39, but otherwise harbors a long ORF for an N-terminally truncated 475 amino acid Env protein, starting at an in-frame ATG at codon 68. We set out to characterize the protein encoded by that ORF.
resultsTransient expression of the 475 amino acid Xq22.3 HERV-W env ORF produced an N-terminally truncated HERV-W Env protein, as detected by the monoclonal anti-HERV-W Env antibodies 6A2B2 and 13H5A5. Remarkably, reversion of the stop at codon 39 in Xq22.3 HERV-W env reconstituted a full-length HERV-W Xq22.3 Env protein. Similar to the full-length HERV-W Env protein Syncytin-1, reconstituted full-length Xq22.3 HERV-W Env is glycosylated, forms oligomers, and is expressed at the cell surface. In contrast, Xq22.3 HERV-W Env is unglycosylated, does not form oligomers, and is located intracellularly, probably due to lack of a signal peptide. Finally, we reconfirm by immunohistochemistry that monoclonal antibody 6A2B2 detects an antigen expressed in placenta and multiple sclerosis brain lesions.
conclusionsA partially defective HERV-W env gene located on chromosome Xq22.3, which we propose to designate ERVWE2, has retained coding capacity and can produce ex vivo an N-terminally truncated Env protein, named N-Trenv. Detection of an antigen by 6A2B2 in placenta and multiple sclerosis lesions opens the possibility that N-Trenv could be expressed in vivo. More generally, our findings are compatible with the idea that defective HERV elements may be capable of producing incomplete HERV proteins that, speculatively, may exert functions in human physiology or pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.